The blood malignancy known as chronic myeloid leukaemia (CML), also called chronic myelogenous leukaemia, primarily affects the bone marrow and blood cells. It belongs to the larger class of malignancies known as leukaemia, which includes those that start in the bone marrow and impact blood cell formation.
Tyrosine Kinase Inhibitors (TKIs): TKIs are the cornerstone of CML treatment. The active component of the Bonitar 400mg Tablet is bosutinib. It is a member of the class of drugs known as tyrosine kinase inhibitors. They work by blocking the activity of the BCR-ABL1 tyrosine kinase protein, thereby inhibiting the uncontrolled growth of abnormal white blood cells. Some of the commonly used TKIs for CML treatment include:
Imatinib : The first TKI developed for CML. It has been highly effective for many patients, especially those in the chronic phase of the disease. Chronic Myeloid Leukaemia Treatment